July 27, 2017 04:18 AM EDT
Pharma

Astel­las is shut­ter­ing Agen­sys, ax­ing 220 jobs and mov­ing away from ADC tech

Arsalan Arif

Founder

A decade ago Agen­sys’ an­ti­body work looked so ap­peal­ing that Astel­las hap­pi­ly paid $387 mil­lion in cash for it, re­serv­ing $150 mil­lion more in mile­stones …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK sues Mod­er­na over mR­NA vac­cine patents, seeks 'rea­son­able roy­al­ty'

J&J trims pipeline, in­clud­ing two mid-stage neu­ro­science stud­ies

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Mary­land biotech gets green light for stem cell-de­rived ther­a­py for di­a­betes, aim­ing to com­pete with Ver­tex

Wal­greens plans to close 1,200 phar­ma­cies

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times